<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674947</url>
  </required_header>
  <id_info>
    <org_study_id>207ST101</org_study_id>
    <nct_id>NCT00674947</nct_id>
  </id_info>
  <brief_title>A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with
      relapsed or refractory solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety</measure>
    <time_frame>ongoing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum-tolerated dose (MTD)</measure>
    <time_frame>ongoing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacokinetics (PK)</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical activity</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB015</intervention_name>
    <description>IV infusion once every 3 weeks until disease progression or unacceptable toxicity</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age 18 years or older at the time of informed consent.

          -  Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic
             therapy and for which no standard therapy exists.

          -  ECOG Performance Status &lt;/= 2.

        Exclusion Criteria

          -  History of keratoconjunctivitis, open or closed angle glaucoma, or &quot;dry eye&quot; disease.

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure.

          -  History of myocardial infarction within 6 months prior to Day 1.

          -  Presence of &gt;/= Grade 2 peripheral neuropathy.

          -  Known presence of central nervous system or brain metastases.

          -  Prior therapy with a conjugated or unconjugated maytansine derivative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <name_title>Julie Morrissey</name_title>
    <organization>Quintiles, Inc.</organization>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

